Concerning Side Effects of Temporal Arteritis Treatment
The most concerning side effects of temporal arteritis treatment stem from prolonged high-dose glucocorticoid therapy, which causes serious adverse events in approximately 60% of patients and includes osteoporosis with fractures, diabetes, hypertension, cardiovascular disease, glaucoma, cataracts, weight gain, and increased infection risk. 1, 2, 3
Glucocorticoid-Related Toxicity (Primary Concern)
Glucocorticoids remain the only proven first-line therapy for GCA, but their required long-term use (1-5 years or more) creates substantial morbidity:
- Metabolic complications: New-onset or worsened diabetes mellitus, hypertension requiring antihypertensive agents, and significant weight gain 4, 5
- Musculoskeletal damage: Osteoporosis with increased fracture risk (particularly concerning in elderly patients), requiring vitamin D, calcium supplementation, and potentially bisphosphonates 4, 5
- Ophthalmologic toxicity: Glucocorticoid-induced cataracts and glaucoma, which ironically compound the vision-threatening nature of untreated GCA itself 5
- Gastrointestinal risks: Peptic ulcer disease and GI bleeding, especially when combined with aspirin (which may be used adjunctively despite lack of RCT evidence), necessitating H2-blockers or proton pump inhibitors 6, 5
- Infectious complications: Increased susceptibility to chronic infections, particularly problematic in immunosenescent elderly patients 4
- Cardiovascular events: Myocardial infarction and cerebrovascular accidents occur with increased frequency, especially early in the disease course when inflammation is active 7
High-Risk Patient Populations Requiring Glucocorticoid-Sparing Strategies
Patients with pre-existing comorbidities face compounded risk and should receive early adjunctive therapy with methotrexate (7.5-10 mg/week) or tocilizumab:
- Diabetes mellitus (uncontrolled or requiring insulin) 4
- Osteoporosis with recent fracture history 4
- Glaucoma or significant cataract disease 4
- Uncontrolled hypertension or established cardiovascular disease 4
- History of chronic infections 4
Disease-Related Complications (Despite Treatment)
Even with appropriate glucocorticoid therapy, ischemic complications can still occur:
- Permanent vision loss: Sudden, irreversible blindness from anterior ischemic optic neuropathy or central retinal artery occlusion remains the most feared complication, occurring in up to 15-20% of untreated patients 3, 5
- Stroke: Cranial ischemia affecting posterior circulation 1, 7
- Aortic involvement: Aneurysm formation, dissection, and large-vessel stenosis develop over time and may not be prevented by glucocorticoids alone 3, 8
- Disease relapse: Flares occur commonly during glucocorticoid taper (in up to 50% of patients), requiring dose escalation and prolonging exposure to steroid toxicity 3, 7
Alternative Therapy Considerations and Their Limitations
Methotrexate (7.5-10 mg/week) is the only conventional DMARD with conditional recommendation for glucocorticoid-sparing, but evidence is mixed and it does not eliminate steroid need: 4
Tocilizumab (IL-6 receptor antagonist) demonstrates superior efficacy in achieving sustained remission and reducing cumulative glucocorticoid exposure in phase III trials, but has not yet proven reduction in glucocorticoid-related adverse outcomes: 4
TNF-α inhibitors (infliximab, etanercept, adalimumab) have case reports suggesting benefit in refractory disease, but lack high-quality evidence and are strongly recommended against for routine use: 1, 4, 2
Upadacitinib (JAK inhibitor) recently approved for GCA shows promise in refractory cases intolerant to tocilizumab, but real-world safety data remain limited: 9
Critical Monitoring Requirements
To detect and mitigate treatment-related toxicity, assess patients every 4-8 weeks during the first year:
- Clinical symptoms of disease activity (headache, jaw claudication, visual changes, constitutional symptoms) 4
- Inflammatory markers (ESR/CRP), though these should not be used in isolation to escalate glucocorticoid doses after initial treatment, as elevations may be unrelated to GCA activity 5
- Glucocorticoid-related adverse events: blood glucose, blood pressure, weight, bone density (DEXA scan at baseline and periodically), ophthalmologic examination for cataracts/glaucoma 4, 5
- Cardiovascular risk assessment, particularly in the first 6-12 months when ischemic event risk is highest 7
Common Pitfalls to Avoid
Do not increase glucocorticoid doses based solely on ESR/CRP elevation without clinical symptoms after the initial treatment phase—this leads to unnecessary steroid toxicity: 5
Do not attribute all visual symptoms to active GCA during treatment—consider glucocorticoid-induced cataracts, tear film abnormalities, and other age-related ophthalmologic conditions: 5
Do not use NSAIDs as primary therapy for GCA—they are ineffective for disease control and only appropriate for short-term management of coexisting musculoskeletal pain: 4
Do not delay temporal artery biopsy beyond 2 weeks of starting glucocorticoids, as diagnostic yield decreases (though histopathologic changes can persist much longer): 1